These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 19572353)

  • 1. [Technological and biopharmaceutical aspects. Antiplatelet agents for oral administration].
    Breitkreutz J
    Pharm Unserer Zeit; 2009; 38(4):330-7. PubMed ID: 19572353
    [No Abstract]   [Full Text] [Related]  

  • 2. Bedside evaluation of thienopyridine antiplatelet therapy.
    Price MJ
    Circulation; 2009 May; 119(19):2625-32. PubMed ID: 19451364
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events.
    Passacquale G; Ferro A
    BMJ; 2011 Jun; 342():d3488. PubMed ID: 21685436
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].
    Alban S
    Pharm Unserer Zeit; 2009; 38(4):320-8. PubMed ID: 19572350
    [No Abstract]   [Full Text] [Related]  

  • 5. [Diagnosis, causes, relevance of a complex phenomenon. Resistance to aspirin and clopidogrel].
    Mani H; Lindhoff-Last E
    Pharm Unserer Zeit; 2009; 38(4):342-50. PubMed ID: 19572355
    [No Abstract]   [Full Text] [Related]  

  • 6. Can we override clopidogrel resistance?
    Pena A; Collet JP; Hulot JS; Silvain J; Barthélémy O; Beygui F; Funck-Brentano C; Montalescot G
    Circulation; 2009 Jun; 119(21):2854-7. PubMed ID: 19487603
    [No Abstract]   [Full Text] [Related]  

  • 7. Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
    Ernest CS; Small DS; Rohatagi S; Salazar DE; Wallentin L; Winters KJ; Wrishko RE
    J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):593-618. PubMed ID: 19023649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmazie in unserer Zeit 4/2009].
    Alban S; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):295. PubMed ID: 19572344
    [No Abstract]   [Full Text] [Related]  

  • 9. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel (Effient) vs. clopidogrel (Plavix).
    Med Lett Drugs Ther; 2009 Sep; 51(1320):69-70. PubMed ID: 19738549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual antiplatelet therapy -- management in general practice.
    Jayasinghe R; Markham R; Adsett G
    Aust Fam Physician; 2013 Oct; 42(10):702-5. PubMed ID: 24130971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.
    Angiolillo DJ; Saucedo JF; Deraad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Effron MB;
    J Am Coll Cardiol; 2010 Sep; 56(13):1017-23. PubMed ID: 20846599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel offers consistent platelet control in appropriate patients requiring treatment.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(2):107, 109. PubMed ID: 21556460
    [No Abstract]   [Full Text] [Related]  

  • 14. [Do genetic factors reduce the effects of clopidogrel?].
    Scharf RE
    Dtsch Med Wochenschr; 2011 Apr; 136(15):786. PubMed ID: 21469049
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
    Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
    Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prasugrel.
    Tantry US; Bliden KP; Gurbel PA
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1627-33. PubMed ID: 17107286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.
    Lenz T; Wilson A
    Clin Pharmacokinet; 2003; 42(10):909-20. PubMed ID: 12885264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI?
    Graber MA; Dachs R; Darby-Stewart A
    Am Fam Physician; 2008 Dec; 78(11):1252-3. PubMed ID: 19069017
    [No Abstract]   [Full Text] [Related]  

  • 19. Prasugrel development - claims and achievements.
    Serebruany V; Shalito I; Kopyleva O
    Thromb Haemost; 2009 Jan; 101(1):14-22. PubMed ID: 19132184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response variability and the role of platelet function testing.
    Gurbel PA; Mahla E; Antonino MJ; Tantry US
    J Invasive Cardiol; 2009 Apr; 21(4):172-8. PubMed ID: 19342756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.